Recombinant Immunoassay Diagnoses Human Fascioliasis
|
By LabMedica International staff writers Posted on 03 Oct 2013 |
|
Image: Adult of Fasciola hepatica stained with carmine (Photo courtesy of US Centers for Disease Control).
The current diagnosis of human fascioliasis involves the detection of eggs in the stool, however, eggs are not observed during the acute phase when the parasite is migrating through the tissues.
A human immune response to Fasciola antigens occurs early in infection, therefore, an immunological method such as an enzyme-linked immunosorbent assay (ELISA) may be a more reliable, easy and cheap means to diagnose human fascioliasis than coprological analysis.
Scientists from McGill University (Montreal, QC, Canada) collected serum samples from 93 Cuban individuals that were coprologically positive for eggs of F. hepatica and clinically diagnosed in the hospital. Samples were also collected from 72 Cuban and 63 Canadian individuals that were shown to be negative for Fasciola infection, and 158 serum samples obtained from individuals infected with other parasitic diseases. The ELISA test was optimized using a recombinant form of the major F. hepatica cathepsin L1 protease antigen (FhCL1).
The ELISA test using anti-total immunoglobulin G (IgG) secondary antibody gave 99.99% specificity and also exhibited 99.99% sensitivity for identifying infected individuals. The results showed that absorbance readings obtained with sera from patients infected with parasites other than F. hepatica closely matched that obtained with the negative control samples. The investigators found that using 0.55 optical density (OD) units as cut-off with anti-total IgG as secondary antibody, the test can discriminate between F. hepatica patients and all other infections examined.
The authors concluded that their standardized ELISA test using a highly stable recombinant form of cathepsin L1, FhCL1, exhibits high sensitivity and specificity and with no cross-reaction with other parasitic diseases. High production of this enzyme can be obtained by purification of Pichia pastoris culture medium, which provides sufficient quantities of material to supply diagnostic centers for mass screening in regions where human fascioliasis is prevalent. The study was published on September 19, 2013, in the journal Public Library of Science Neglected Tropical Disease.
Related Links:
McGill University
.jpg)
A human immune response to Fasciola antigens occurs early in infection, therefore, an immunological method such as an enzyme-linked immunosorbent assay (ELISA) may be a more reliable, easy and cheap means to diagnose human fascioliasis than coprological analysis.
Scientists from McGill University (Montreal, QC, Canada) collected serum samples from 93 Cuban individuals that were coprologically positive for eggs of F. hepatica and clinically diagnosed in the hospital. Samples were also collected from 72 Cuban and 63 Canadian individuals that were shown to be negative for Fasciola infection, and 158 serum samples obtained from individuals infected with other parasitic diseases. The ELISA test was optimized using a recombinant form of the major F. hepatica cathepsin L1 protease antigen (FhCL1).
The ELISA test using anti-total immunoglobulin G (IgG) secondary antibody gave 99.99% specificity and also exhibited 99.99% sensitivity for identifying infected individuals. The results showed that absorbance readings obtained with sera from patients infected with parasites other than F. hepatica closely matched that obtained with the negative control samples. The investigators found that using 0.55 optical density (OD) units as cut-off with anti-total IgG as secondary antibody, the test can discriminate between F. hepatica patients and all other infections examined.
The authors concluded that their standardized ELISA test using a highly stable recombinant form of cathepsin L1, FhCL1, exhibits high sensitivity and specificity and with no cross-reaction with other parasitic diseases. High production of this enzyme can be obtained by purification of Pichia pastoris culture medium, which provides sufficient quantities of material to supply diagnostic centers for mass screening in regions where human fascioliasis is prevalent. The study was published on September 19, 2013, in the journal Public Library of Science Neglected Tropical Disease.
Related Links:
McGill University
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
All-in-One Molecular System
AIO M160
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Latest Immunology News
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Molecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
Immunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more
Pathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read more
Technology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Industry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more